With the increasing “Maskne” phenomenon and the requirement of anti-acne solutions, StratiCELL has decided to expand its range of in vitro testing related to Cutibacterium acnes. The provider of in vitro testing opened last year its MicroBIOS Platform where its 3D skin models are colonized with living cutaneous strains including C. acnes. To support dermo-cosmetic actors in defining anti-acneic properties, StratiCELL offers a double complementary testing approach: define the impact of cosmetic actives on the bacterial growth on one hand, and on the response of the epidermis to this infectious context on the other hand. Colonisation by C. acnes indeed generates an inflammatory reaction which can be characterised in particular by an increase in interleukins and other pro-inflammatory molecules such as COX-2, TNF-alpha, or the defensin HBD-2. The ability of an active ingredient to reduce this inflammatory status can therefore be objectively assessed by monitoring expression of these key biomarkers, at the gene level and at the protein level. Data generated could clearly support the introduction of innovative actives fighting the C. acnes inflammatory threat into the dermo-cosmetic market.